# Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline Dystrophy

> **NCT06699108** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Vitalgen BioPharma Co., Ltd.** · enrollment: 45 (estimated)

## Conditions studied

- Bietti Crystalline Dystrophy
- Inherited Retinal Diseases

## Interventions

- **DRUG:** VGR-R01

## Key facts

- **NCT ID:** NCT06699108
- **Lead sponsor:** Shanghai Vitalgen BioPharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-13
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-06-30
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06699108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06699108, "Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline Dystrophy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06699108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*